GICS Sector : Healthcare
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms.
scPharmaceuticals reported a significant increase in net revenue for Q2 2025, reaching $16 million, a 99% increase over Q2 2024. The company's gross to net discount was approximately 27%, and it expects this to approach 30% in Q3 2025. The actual EPS came out at -$0.34, relative to estimates at -$0.3, indicating a slight deviation from expectations. With a reported 20,200 FUROSCIX doses filled, a 117% increase over Q2 2024, the company's financial performance is on an upward trajectory.
Publication Date: Aug -26
The growth in revenue can be attributed to several factors, including uptake in nephrology, evolving Part D dynamics, and advancements in the IDN business. According to Steve Parsons, SVP of Commercial, the company had approximately 4,700 unique cardiology and nephrology prescribers, a number that continues to increase. The sales force expansion in Q4 2024 has shown a significant return on investment, and the company expects the sales force to continue to drive growth in the second half of 2025.
As of Q2 2025, scPharmaceuticals ended with $40.8 million in cash and cash equivalents, providing a solid foundation for future operations. Management addressed concerns regarding the company's cash runway during the Q&A session, though specific details on the cash runway were not disclosed.
With a P/S Ratio of 5.9, the market is pricing in significant revenue growth, which is expected to continue with analysts estimating an 81.1% revenue growth for the next year. The ROE and ROIC are negative, indicating that the company is still in a growth phase and not yet profitable. The EV/EBITDA ratio is -3.71, further highlighting the company's current financial situation.
The company also discussed the Ambulatory Specialty Model (ASM) proposed by CMS, expected to be implemented in January 2027. Management believes this model aligns with FUROSCIX's value proposition, potentially driving further growth. This development, combined with the company's expanding sales force and increasing prescriber base, positions scPharmaceuticals for continued success.
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
Aug -26
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
Aug -26
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
Aug -25
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
Aug -25
Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders
Aug -25
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
Aug -25
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
Aug -14
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
Aug -08
Strong pipeline of innovative products, increasing demand for rare disease treatments, strategic partnerships, and expansion into emerging markets drive scPharmaceuticals Inc.'s 8.5% growth in pharmaceutical products. Additionally, investments in digital healthcare and personalized medicine contribute to the company's accelerated growth.
Furoscix is a proprietary, subcutaneously administered furosemide solution for the treatment of congestion in patients with heart failure.
SUFU is a wearable, patch-based system that delivers furosemide subcutaneously, providing an alternative to traditional IV administration.
The threat of substitutes for scPharmaceuticals Inc. is medium due to the presence of alternative products and services in the market.
The bargaining power of customers for scPharmaceuticals Inc. is low due to the lack of concentration of buyers in the market.
The bargaining power of suppliers for scPharmaceuticals Inc. is high due to the concentration of suppliers in the market.
The threat of new entrants for scPharmaceuticals Inc. is medium due to the moderate barriers to entry in the market.
The intensity of rivalry for scPharmaceuticals Inc. is high due to the high level of competition in the market.
| Value | |
|---|---|
| Debt Weight | 51.16% |
| Debt Cost | 4.37% |
| Equity Weight | 48.84% |
| Equity Cost | 4.37% |
| WACC | 4.37% |
| Leverage | 104.75% |
Value: 10.0
Growth: 2.4
Quality: 7.2
Yield: 0.0
Momentum: 9.0
Volatility: 0.7
1-Year Total Return ->
Value: 8.2
Growth: 4.7
Quality: 4.5
Yield: 0.0
Momentum: 9.0
Volatility: 2.3
1-Year Total Return ->
Value: 8.2
Growth: 5.0
Quality: 4.6
Yield: 0.0
Momentum: 8.0
Volatility: 1.3
1-Year Total Return ->
Value: 7.0
Growth: 5.7
Quality: 4.7
Yield: 0.0
Momentum: 9.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.2
Growth: 4.6
Quality: 3.3
Yield: 0.0
Momentum: 6.0
Volatility: 2.0
1-Year Total Return ->
Value: 9.2
Growth: 4.8
Quality: 5.8
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->